News

Meet Your 2020 BioBuzz Award Winners

BioBuzz-Award-Winners-featured-image

Today, we are excited to announce the winners of our inaugural BioBuzz Awards. The BioBuzz Awards are a celebration of the exciting and groundbreaking work being done by the BioHealth Capital Region (BHCR) life science community and the individuals that make innovation happen across Maryland, Virginia, and Washington, D.C. The award categories include: The Community Impact Leader […]

MapLight Therapeutics Receives $8.1 Million For Parkinson’s Disease Research

MapLight

SAN FRANCISCO, Nov. 30, 2020 /PRNewswire/ — MapLight Therapeutics today announced a $8.1 million grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), to undertake a large-scale, systematic investigation of the brain circuits and mechanisms that are responsible for triggering psychiatric symptoms in Parkinson’s disease. Results will inform identification of novel drug targets and therapeutic strategies to […]

Comments Off on MapLight Therapeutics Receives $8.1 Million For Parkinson’s Disease Research Continue Reading →

GlycoMimetics CEO Rachel King Featured in “Her Story” Podcast Along with BIO’s Dr. Michelle McMurry-Heath

Rachel 2018-09-28 Glycomimetics retouch-2-2

In this conversation, Ms. King and Dr. McMurry-Heath share stories underlying their careers in scientific innovation, from the lab bench to government, consulting, and venture capital; and their experiences as one of the few women CEOs in biotechnology.

Comments Off on GlycoMimetics CEO Rachel King Featured in “Her Story” Podcast Along with BIO’s Dr. Michelle McMurry-Heath Continue Reading →

BioBuzz: Cartesian Therapeutics Pipeline Showcased Among Cutting-Edge Therapies in BioHealth Capital Region

Cartesian Logo New JPG

Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum. The Strengths of our Region: Cutting Edge Therapies panel, which was moderated by Mark Cobbold, vice president of Discovery in […]

Comments Off on BioBuzz: Cartesian Therapeutics Pipeline Showcased Among Cutting-Edge Therapies in BioHealth Capital Region Continue Reading →

Top Firms Form ‘Rapid Reshore & Development’ to Serve Life Sciences Industry

RR&D_Logo

Rapid Reshore & Development (RR&D), an alliance of three specialized firms coming together to provide turnkey professional services for the life sciences and biopharmaceutical industries, has announced its official launch to address many of the logistical challenges facing companies developing drugs, vaccines and medical devices. RR&D – comprised of Facility Logix, EwingCole and Biggins Lacy Shapiro & Co – will […]

Comments Off on Top Firms Form ‘Rapid Reshore & Development’ to Serve Life Sciences Industry Continue Reading →

Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020

Sagimet

SAN MATEO, Calif., Oct. 6, 2020 /PRNewswire/ — Sagimet Biosciences, a clinical-stage biotechnology company, announced today that new results from its Phase 2 FASCINATE-1 trial of TVB-2640 in nonalcoholic steatohepatitis (NASH) will be shared in an oral presentation at The Liver Meeting Digital Experience™ 2020 of the American Association for the Study of Liver Diseases (AASLD) to be […]

Comments Off on Sagimet to Present Data from Phase 2 FASCINATE-1 Trial of TVB-2640 in NASH at AASLD’s The Liver Meeting Digital Experience™ 2020 Continue Reading →

FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease

logo-glyco

ROCKVILLE, Md.–(BUSINESS WIRE)–Oct. 5, 2020– GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that the U.S. Food and Drug Administration (FDA) has granted the Company a Rare Pediatric Disease designation for rivipansel for the treatment of sickle cell disease in patients 18 years old and younger. This designation recognizes the significant needs in pediatric patients. “The FDA’s designation recognizes the morbidity […]

Comments Off on FDA Grants GlycoMimetics Rare Pediatric Disease Designation for Rivipansel for Treatment of Sickle Cell Disease Continue Reading →

GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo

GlycoT

BALTIMORE, Sept. 14, 2020 /PRNewswire/ — GlycoT Therapeutics LLC, a UM Ventures start-up company based on intellectual property (IP) developed at the University of Maryland, Baltimore (UMB) and University of Maryland, College Park (UMCP), has executed a sublicense agreement for its glycoengineering technology with Daiichi Sankyo Company, Limited (Daiichi Sankyo; www.daiichisankyo.com). The agreement grants Daiichi Sankyo worldwide and non-exclusive rights to IP that GlycoT currently licenses from UMB […]

Comments Off on GlycoT Therapeutics Grants Sublicense of Glycoengineering Technology to Daiichi Sankyo Continue Reading →

BioBuzz: MaxCyte Appoints Amanda L. Murphy as CFO, Names Ron Holtz as SVP & CAO

Maxcyte logo square

Murphy brings a wealth of life sciences capital markets experience and deep knowledge in the enabling technologies and cell therapy sectorsHoltz to remain on the Board of Directors of the Company and retain key elements of his executive role, including overseeing accounting, budgeting, and supporting key business operations Gaithersburg, Maryland – September 9, 2020: — MaxCyte, […]

Comments Off on BioBuzz: MaxCyte Appoints Amanda L. Murphy as CFO, Names Ron Holtz as SVP & CAO Continue Reading →